Clinical trial · Interventional
Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer
NCT06364748CI-TRIAL-00123192terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Dr. Shalowitz resigned from the West Michigan Cancer Center. Target enrollment was 60 and only 18 were analyzed. No conclusions can be drawn from this interim analysis.
Summary
Brief summary (as posted)
A randomized trial of remote blood pressure monitoring, compared to usual care, in patients receiving bevacizumab to determine whether remote blood pressure monitoring improves the collection of blood pressure data, identification and management of clinically significant hypertension, and patient satisfaction.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cellular enabled blood pressure cuff | Device | — | UNRESOLVED |
| Standard of Care Cuff | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Smart Cuff Group
- description
- Smart blood pressure cuff
- interventionNames
- Device: Cellular enabled blood pressure cuff
- type
- PLACEBO_COMPARATOR
- label
- Control Group
- description
- Standard of care
- interventionNames
- Device: Standard of Care Cuff
Primary outcomes (1)
- measure
- To determine whether remote blood pressure monitoring improves adherence to recommendations for daily systolic and diastolic blood pressure monitoring compared to usual care
- timeFrame
- Through study completion, an average of 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participant is a male or female 18 years of age or older. 2. Participant is a current patient at West Michigan Cancer Center/Bronson Cancer Center. 3. Participant is receiving bevacizumab as part of active treatment. 4. Participant is willing and able to provide written informed consent. Exclusion Criteria: 1. Participant is unable to understand English. 2. Participant is hospitalized. 3. Participants are unable to obtain blood pressure readings at home.
References
Publications (0)
Data not yet available
No reference posted for this study.